Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75


Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer.

Nguyen DJM, Theodoropoulos G, Li YY, Wu C, Sha W, Feun LG, Lampidis TJ, Savaraj N, Wangpaichitr M.

Mol Cancer Res. 2019 Oct 18. doi: 10.1158/1541-7786.MCR-19-0239. [Epub ahead of print]


Combining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress.

Liu H, Kurtoglu M, León-Annicchiarico CL, Munoz-Pinedo C, Barredo J, Leclerc G, Merchan J, Liu X, Lampidis TJ.

Oncotarget. 2016 Jun 14;7(24):36461-36473. doi: 10.18632/oncotarget.9263.


2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation.

Kovács K, Decatur C, Toro M, Pham DG, Liu H, Jing Y, Murray TG, Lampidis TJ, Merchan JR.

Mol Cancer Ther. 2016 Feb;15(2):264-75. doi: 10.1158/1535-7163.MCT-14-0315. Epub 2015 Dec 4.


Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.

Leclerc GJ, DeSalvo J, Du J, Gao N, Leclerc GM, Lehrman MA, Lampidis TJ, Barredo JC.

Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30360-X. doi: 10.1016/j.leukres.2015.08.007. [Epub ahead of print]


ATF4 mediates necrosis induced by glucose deprivation and apoptosis induced by 2-deoxyglucose in the same cells.

León-Annicchiarico CL, Ramírez-Peinado S, Domínguez-Villanueva D, Gonsberg A, Lampidis TJ, Muñoz-Pinedo C.

FEBS J. 2015 Sep;282(18):3647-58. doi: 10.1111/febs.13369. Epub 2015 Aug 1.


The wonders of 2-deoxy-D-glucose.

Xi H, Kurtoglu M, Lampidis TJ.

IUBMB Life. 2014 Feb;66(2):110-21. doi: 10.1002/iub.1251. Epub 2014 Feb 27.


Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.

Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, Lampidis TJ.

Cancer Chemother Pharmacol. 2014 Feb;73(2):417-27. doi: 10.1007/s00280-013-2366-8. Epub 2013 Dec 19.


Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose.

Philips KB, Kurtoglu M, Leung HJ, Liu H, Gao N, Lehrman MA, Murray TG, Lampidis TJ.

Cancer Chemother Pharmacol. 2014 Feb;73(2):349-61. doi: 10.1007/s00280-013-2358-8. Epub 2013 Dec 1.


Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells.

Liu H, Kurtoglu M, Cao Y, Xi H, Kumar R, Axten JM, Lampidis TJ.

Cancer Chemother Pharmacol. 2013 Jul;72(1):251-62. doi: 10.1007/s00280-013-2193-y. Epub 2013 May 23.


Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy.

Xi H, Barredo JC, Merchan JR, Lampidis TJ.

Biochem Pharmacol. 2013 May 15;85(10):1463-77. doi: 10.1016/j.bcp.2013.02.037. Epub 2013 Mar 13.


Models and discovery strategies for new therapies of retinoblastoma.

Houston SK, Lampidis TJ, Murray TG.

Expert Opin Drug Discov. 2013 Apr;8(4):383-94. doi: 10.1517/17460441.2013.772975. Epub 2013 Feb 22. Review.


A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.

Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ.

Cancer Chemother Pharmacol. 2013 Feb;71(2):523-30. doi: 10.1007/s00280-012-2045-1. Epub 2012 Dec 11.


Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression.

Leung HJ, Duran EM, Kurtoglu M, Andreansky S, Lampidis TJ, Mesri EA.

Antimicrob Agents Chemother. 2012 Nov;56(11):5794-803. doi: 10.1128/AAC.01126-12. Epub 2012 Aug 27.


Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.

Piña Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ.

Clin Ophthalmol. 2012;6:817-30. doi: 10.2147/OPTH.S29688. Epub 2012 May 29.


Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia.

DeSalvo J, Kuznetsov JN, Du J, Leclerc GM, Leclerc GJ, Lampidis TJ, Barredo JC.

Mol Cancer Res. 2012 Jul;10(7):969-78. doi: 10.1158/1541-7786.MCR-12-0125. Epub 2012 Jun 12.


The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells.

Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT, Savaraj N.

Mol Cancer Ther. 2012 Mar;11(3):604-15. doi: 10.1158/1535-7163.MCT-11-0599. Epub 2012 Jan 16.


Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors.

Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C, Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ.

Clin Ophthalmol. 2011 Jan 27;5:129-37. doi: 10.2147/OPTH.S15179.


Antiangiogenic activity of 2-deoxy-D-glucose.

Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ.

PLoS One. 2010 Oct 27;5(10):e13699. doi: 10.1371/journal.pone.0013699.


Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma.

Piña Y, Houston SK, Murray TG, Boutrid H, Celdran M, Feuer W, Shi W, Hernandez E, Lampidis TJ.

Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6149-56. doi: 10.1167/iovs.09-5033. Epub 2010 Aug 11.


2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion.

Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N, Lampidis TJ.

Cancer Chemother Pharmacol. 2011 Apr;67(4):899-910. doi: 10.1007/s00280-010-1391-0. Epub 2010 Jul 1.

Supplemental Content

Loading ...
Support Center